Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MEDCO MAIL-ORDER IS NOT PART OF MERCK "COORDINATED PHARMACEUTICAL CARE"

Executive Summary

MEDCO MAIL-ORDER IS NOT PART OF MERCK "COORDINATED PHARMACEUTICAL CARE" vision, Merck U.S. Human Health President Richard Lane maintained during an Oct. 25 special "town hall" session of NARD's annual meeting in Indianapolis. Lane emphasized that Merck has entered into an agreement to purchase "Medco because of [Medco's] information system capabilities," so that Merck can use them to coordinate pharmaceutical care in a way that involves community pharmacy and pays pharmacists for that involvement. The turbulent relationship between Medco and retail pharmacy has been a sticking point for the Merck/Medco merger from its announcement ("The Pink Sheet" Aug. 2, p. 6). Lane's appearance before NARD reflected that difficulty, as several independent pharmacy owners reported that they previously respected Merck because of its one-price policy but now strive to fill prescriptions for Merck drugs with other companies' products. NARD Exec Committee member Louis Mitchell asked whether Merck would divest Medco's mail-service operation, if that Medco operation is not part of the "coordinated pharmaceutical care" vision. Lane replied that legal restrictions prevented him from disclosing details of Merck's plans for a company it does not yet own. Lane announced that, in an effort to make Merck "a more customer-focused organization," the company is restructuring its U.S. pharmaceutical business into six customer business units. One of the new units will be "focused directly on pharmacy," Lane said. "The unit "will have the objective of working with pharmacy to develop business-to-business relationships, win-win opportunities for meeting patient needs and enhancing the long- term profitability of both Merck and for pharmacy," he declared. "It is our vision that, working with the information systems of Medco, we can include pharmacy more actively in providing care and remunerate pharmacy for being involved in providing that care," Lane said. "Merck believes there's a significant opportunity for us to work with you in the new information systems that we see for the future to assure an appropriate active role for [the community pharmacist] in delivering cost-effective health care, with utilization review, outcome management and direct dialogue with patients." Merck, Lane said, wants "to give physicians and community pharmacists access to information systems that ensure that [health care] is integrated and monitored on a continuing basis." However, he said, "Merck couldn't do that with the skills we had, and that's why we went out and bought Medco."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS023520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel